SEC Comment Letter for Processa Pharmaceuticals, Inc. (PCSA) (CIK 0001533743) (PCSA) — Oct 24, 2018

Processa Pharmaceuticals, Inc. (PCSA) (CIK 0001533743)
Date: Oct. 24, 2018 · CIK: 0001533743 · Accession: 0000000000-18-033342

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-184948

Date

October 24, 2018

Author

David Young

Form

UPLOAD

Company

Processa Pharmaceuticals, Inc. (PCSA) (CIK 0001533743)

Letter

October 24, 2018 David Young Chief Executive Officer Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive, Suite 106 Hanover, MD 21076 Re:Processa Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2017 Filed April 16, 2018 (as amended on April 17, 2018) Form 10-Q for the Quarterly Period Ended March 31, 2018 Filed May 21, 2018 File No. 333-184948 Dear Dr. Young: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Neda A. Sharifi

Show Raw Text

October 24, 2018
David Young
Chief Executive Officer
Processa Pharmaceuticals, Inc.
7380 Coca Cola Drive, Suite 106
Hanover, MD 21076
Re:Processa Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2017
Filed April 16, 2018 (as amended on April 17, 2018)
Form 10-Q for the Quarterly Period Ended March 31, 2018
Filed May 21, 2018
File No. 333-184948
Dear Dr. Young:
            We have completed our review of your filings.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc:       Neda A. Sharifi

SecProbe.io